A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.

ABSTRACT:

Objective

To improve prediction, the AJCC staging system was revised to be consistent with upfront surgery (UFS) and neoadjuvant therapy (NAT) for PDAC.

Background

The AJCC staging system was designed for patients who have had UFS for PDAC, and it has limited predictive power for patients receiving NAT.

Methods

We examined 146 PDAC patients who had resection after NAT and 1771 who had UFS at Changhai Hospital between 2012 and 2021. The clinicopathological factors were identified using Cox proportional regression analysis, and the Neoadjuvant Therapy Compatible Prognostic (NATCP) staging was developed based on these variables. Validation was carried out in the prospective NAT cohort and the SEER database. The staging approach was compared to the AJCC staging system reg

SUBMITTER: Zhu L 

PROVIDER: S-EPMC10463422 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature